世界のヒトマイクロバイオーム市場予測(~2028年):製品別(プレバイオティクス、プロバイオティクス、食品、診断検査、薬剤)、用途別(治療、診断)、疾患別(感染性、代謝/内分泌)、研究技術別(ゲノミクス、プロテオミクス、メタボロミクス)

◆英語タイトル:Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2028
◆商品コード:BT2711
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年3月17日
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は世界のヒトマイクロバイオーム市場規模が2025年894百万ドルから2028年1,598百万ドルまで、年平均21.3%成長すると予想しています。本市場調査資料では、ヒトマイクロバイオームの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(薬剤、診断検査、プロバイオティクス、プレバイオティクス、その他)分析、疾患別(感染症、胃腸疾患、内分泌・代謝障害、がん、その他)分析、用途別(治療用、診断用)分析、技術別(ゲノミクス、プロテオミクス、メタボロミクス)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のヒトマイクロバイオーム市場規模:製品別(薬剤、診断検査、プロバイオティクス、プレバイオティクス、その他)
・世界のヒトマイクロバイオーム市場規模:疾患別(感染症、胃腸疾患、内分泌・代謝障害、がん、その他)
・世界のヒトマイクロバイオーム市場規模:用途別(治療用、診断用)
・世界のヒトマイクロバイオーム市場規模:技術別(ゲノミクス、プロテオミクス、メタボロミクス)
・世界のヒトマイクロバイオーム市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.”
The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market’s growth.

“By product segment, the drugs segment accounted for the largest share of human microbiome market.”

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs

“By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period.”
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

“By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market.

“North America: The largest and fastest-growing region in the human microbiome market.”
In the human microbiome market, North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

Breakdown of primaries:
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.
The break-up of the primaries is as follows:
By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%,
By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%

Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), Evelo Biosciences (US), OptiBiotix Health (UK), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), BiomX (Israel), DuPont (US), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).

Research Coverage:
The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 24
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED FOR THE HUMAN MICROBIOME MARKET 24
1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET 25
1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET) 25
1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME DIAGNOSTIC APPLICATIONS MARKETS) 26
1.3.5 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME THERAPEUTIC APPLICATION MARKETS) 26
1.4 CURRENCY 27
1.5 STAKEHOLDERS 27
1.6 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
2.1.1 SECONDARY DATA 28
2.1.2 PRIMARY SOURCES 29
FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET 29
2.2 MARKET DATA ESTIMATION AND TRIANGULATION 30
FIGURE 2 DATA TRIANGULATION METHODOLOGY 30
2.2.1 MARKET ESTIMATION METHODOLOGY 31
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET) 31
FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE 31
2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 32
FIGURE 5 FINAL CAGR PROJECTIONS (2020−2025) 32
2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET 32
FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH 33
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 33
2.3 RESEARCH ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2028 (USD MILLION) 35
FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2024 36
FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2028 (USD MILLION) 36
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE HUMAN MICROBIOME MARKET 37
4 PREMIUM INSIGHTS 38
4.1 HUMAN MICROBIOME: MARKET OVERVIEW 38
FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE THE GROWTH OF THIS MARKET 38
4.2 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (2020 VS. 2025) 39
FIGURE 13 GENOMIC TECHNOLOGIES DOMINATED THE HUMAN MICROBIOME RESEARCH SPENDING MARKET IN 2020 39
4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2024) 40
4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2020–2025) 41
FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 43
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 MARKET DRIVERS 43
5.2.1.1 Increasing focus on human microbiome therapeutics development 43
5.2.1.2 Human microbiome as a validated target for drug development 44
5.2.1.3 Development of human microbiome-based tests for early disease detection & diagnosis 44
5.2.2 MARKET OPPORTUNITIES 45
5.2.2.1 Increasing collaborations between public-private organizations 45
5.2.3 MARKET CHALLENGES 46
5.2.3.1 Government regulations 46
5.2.3.2 Lack of expertise and inadequate research 47
5.2.4 MARKET RESTRAINTS 47
5.2.4.1 Barriers in proving the causal link between dysbiosis and diseases 47
5.3 IMPACT OF THE COVID-19 ON THE MARKET 47
5.4 TECHNOLOGY ANALYSIS 49
5.5 REGULATORY ANALYSIS 49
5.5.1 FOR HUMAN MICROBIOME-BASED DRUGS CATEGORY 49
5.5.2 FOR HUMAN MICROBIOME-BASED FOODS CATEGORY 51
5.6 PATENT ANALYSIS 51
6 HUMAN MICROBIOME MARKET, BY PRODUCT 53
6.1 INTRODUCTION 54
TABLE 1 HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 54
6.2 DRUGS 54
6.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN THE PIPELINE IS A KEY FACTOR DRIVING MARKET GROWTH 54
TABLE 2 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2022–2028 (USD MILLION) 55
TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY 2022–2028 (USD MILLION) 55
6.3 DIAGNOSTIC TESTS 55
6.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME-BASED TESTS TO DRIVE MARKET GROWTH 55
TABLE 4 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2019–2028 (USD MILLION) 56
TABLE 5 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY 2019–2028 (USD MILLION) 56
6.4 PROBIOTICS 57
6.4.1 ONGOING RESEARCH ON PROBIOTICS IS PROMOTING ITS CREDIBILITY IN HEALTH CLAIMS AND SAFETY, THUS DRIVING MARKET GROWTH 57
TABLE 6 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2028 (USD MILLION) 57
TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2019–2028 (USD MILLION) 58
6.5 PREBIOTICS 58
6.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA IS THE KEY GROWTH DRIVER FOR THIS SEGMENT 58
TABLE 8 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2028 (USD MILLION) 59
TABLE 9 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023- 2028 (USD MILLION) 59
6.6 OTHER PRODUCTS 59
TABLE 10 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2028 (USD MILLION) 60
TABLE 11 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2028 (USD MILLION) 60
7 HUMAN MICROBIOME MARKET, BY DISEASE 61
7.1 INTRODUCTION 62
TABLE 12 HUMAN MICROBIOME MARKET, BY DISEASE, 2022–2028 (USD MILLION) 62
7.2 INFECTIOUS DISEASES 62
7.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE MARKET GROWTH 62
TABLE 13 DEVELOPMENT OF MICROBIOME-BASED DRUGS FOR INFECTIOUS DISEASES 63
TABLE 14 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2027 (USD MILLION) 63
TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2028 (USD MILLION) 63
7.3 GASTROINTESTINAL DISEASES 64
7.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE MARKET GROWTH 64
TABLE 16 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2028 (USD MILLION) 64
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2028 (USD MILLION) 65
7.4 ENDOCRINE & METABOLIC DISORDERS 65
7.4.1 THE DEVELOPMENT OF MICROBIOME MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS DRIVES MARKET GROWTH 65
TABLE 18 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2022-2028 (USD MILLION) 66
TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2022–2028 (USD MILLION) 66
7.5 CANCER 66
7.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN THE TREATMENT OF PELVIC AND COLON CANCER 66
TABLE 20 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2022–2028 (USD MILLION) 67
TABLE 21 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2022–2028 (USD MILLION) 67
7.6 OTHER DISEASES 67
TABLE 22 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2022–2028 (USD MILLION) 68
TABLE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2028 (USD MILLION) 68
8 HUMAN MICROBIOME MARKET, BY APPLICATION 69
8.1 INTRODUCTION 70
TABLE 24 HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 70
8.2 THERAPEUTIC APPLICATIONS 70
8.2.1 AVAILABILITY OF FUNDING FOR THE DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET GROWTH 70
TABLE 25 HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2019–2028 (USD MILLION) 71
TABLE 26 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2019–2028 (USD MILLION) 71
8.3 DIAGNOSTIC APPLICATIONS 71
8.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH 71
TABLE 27 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2028 (USD MILLION) 72
TABLE 28 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2028 (USD MILLION) 72
9 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY 73
9.1 INTRODUCTION 74
TABLE 29 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 74
9.2 GENOMICS 74
TABLE 30 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2018–2025 (USD MILLION) 74
TABLE 31 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2018–2025 (USD MILLION) 75
TABLE 32 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 75
TABLE 33 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 75
TABLE 34 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 76
9.2.1 SEQUENCING 76
TABLE 35 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2018–2025 (USD MILLION) 76
TABLE 36 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 37 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018–2025 (USD MILLION) 77
TABLE 38 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018–2025 (USD MILLION) 77
TABLE 39 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2018–2025 (USD MILLION) 77
9.2.1.1 16S rRNA Sequencing Method 78
9.2.1.1.1 This method is a cost-effective technique for the identification of bacterial strains 78
TABLE 40 16S RRNA SEQUENCING METHOD, BY REGION, 2018–2025 (USD MILLION) 78
TABLE 41 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 42 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 79
TABLE 43 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 79
9.2.1.2 Whole-Genome Sequencing(WGS)Method 79
9.2.1.2.1 WGS helps generate accurate reference genomes for microbial identification 79
TABLE 44 WGS METHOD, BY REGION, 2018–2025 (USD MILLION) 80
TABLE 45 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 46 EUROPE: WGS METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 47 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2018–2025 (USD MILLION) 80
9.2.1.3 Other Sequencing Methods 81
TABLE 48 OTHER SEQUENCING METHODS, BY REGION, 2018–2025 (USD MILLION) 81
TABLE 49 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 50 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 51 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 2018–2025 (USD MILLION) 82
9.2.2 OTHER GENOMIC TECHNOLOGIES 82
TABLE 52 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2018–2025 (USD MILLION) 82
TABLE 53 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 54 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 55 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018–2025 (USD MILLION) 83
9.3 PROTEOMICS 84
9.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH 84
TABLE 56 PROTEOMICS, BY REGION, 2018–2025 (USD MILLION) 84
TABLE 57 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 84
TABLE 58 EUROPE: PROTEOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 85
TABLE 59 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 85
9.4 METABOLOMICS 85
9.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS IN MICROBIOME RESEARCH TO DRIVE MARKET GROWTH 85
TABLE 60 METABOLOMICS, BY REGION, 2018–2025 (USD MILLION) 86
TABLE 61 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 86
TABLE 62 EUROPE: METABOLOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 86
TABLE 63 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2018–2025 (USD MILLION) 86
10 HUMAN MICROBIOME MARKET, BY REGION 87
10.1 INTRODUCTION 88
TABLE 64 HUMAN MICROBIOME MARKET, BY REGION, 2019–2028 (USD MILLION) 88
TABLE 65 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY REGION, 2018–2025 (USD MILLION) 88
10.2 NORTH AMERICA 89
FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 89
TABLE 66 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 90
TABLE 67 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 90
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION) 91
TABLE 69 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2019–2025 (USD MILLION) 91
TABLE 70 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 91
TABLE 71 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 92
TABLE 72 NORTH AMERICA: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 92
TABLE 73 NORTH AMERICA: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 92
10.2.1 US 93
10.2.1.1 Increasing investments by NIH in support of microbiome research is driving the market growth in the US 93
TABLE 74 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 93
TABLE 75 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 94
TABLE 76 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2022–2028 (USD MILLION) 94
TABLE 77 US: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 95
TABLE 78 US: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 79 US: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 95
10.2.2 CANADA 96
10.2.2.1 Increasing government support and funds support market growth for microbiome research in Canada 96
TABLE 80 INDICATIVE LIST OF PROJECTS ON THE HUMAN MICROBIOME IN 2018 96
TABLE 81 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 97
TABLE 82 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 97
TABLE 83 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION) 98
TABLE 84 CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 98
TABLE 85 CANADA: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 86 CANADA: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 99
10.3 EUROPE 99
TABLE 87 EU MICROBIOME PROJECT 99
TABLE 88 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 99
TABLE 89 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 100
TABLE 90 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2022–2028 (USD MILLION) 100
TABLE 91 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 92 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 101
TABLE 93 EUROPE: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 94 EUROPE: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 102
10.3.1 GERMANY 102
10.3.1.1 Extended applications of microbiome research to therapeutic areas to boost the adoption of microbiome-based products in Germany 102
TABLE 95 GERMANY: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 102
TABLE 96 GERMANY: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 97 GERMANY: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 103
10.3.2 UK 103
10.3.2.1 Increasing focus on the development of microbiome-based products in the UK to drive market growth 103
TABLE 98 UK: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 104
TABLE 99 UK: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 100 UK: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 104
10.3.3 FRANCE 105
10.3.3.1 Increasing funding to boost the development of microbiome-based products in Europe 105
TABLE 101 FRANCE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 105
TABLE 102 FRANCE: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 103 FRANCE: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 106
10.3.4 ROE 106
TABLE 104 ROE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 106
TABLE 105 ROE: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 106 ROE: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 107
10.4 ASIA PACIFIC 107
FIGURE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 108
TABLE 107 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 109
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 109
TABLE 109 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2022–2028 (USD MILLION) 110
TABLE 110 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 110
TABLE 111 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 111
TABLE 112 ASIA PACIFIC: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 111
TABLE 113 ASIA PACIFIC: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 111
10.4.1 CHINA 112
10.4.1.1 A large number of human microbiome research studies are conducted in China, thus driving market growth 112
TABLE 114 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA 112
TABLE 115 CHINA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 113
TABLE 116 CHINA: GENOMICS TECHNOLOGY MARKET, BY TYPE, 2018–2025 (USD MILLION) 113
TABLE 117 CHINA: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 113
10.4.2 JAPAN 114
10.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth 114
TABLE 118 JAPAN: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 114
TABLE 119 JAPAN: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 114
TABLE 120 JAPAN: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 115
10.4.3 INDIA 115
10.4.3.1 Government funding to drive the development of microbiome-based products in India 115
TABLE 121 INDIA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 115
TABLE 122 INDIA: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 123 INDIA: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 116
10.4.4 ROAPAC 116
TABLE 124 ROAPAC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 117
TABLE 125 ROAPAC: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 117
TABLE 126 ROAPAC: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 117
10.5 REST OF THE WORLD (ROW) 118
TABLE 127 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019–2028 (USD MILLION) 118
TABLE 128 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019–2028 (USD MILLION) 119
TABLE 129 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION) 119
TABLE 130 ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION) 120
TABLE 131 ROW: GENOMICS MARKET, BY TYPE, 2018–2025 (USD MILLION) 120
TABLE 132 ROW: SEQUENCING MARKET, BY METHOD, 2018–2025 (USD MILLION) 120
11 COMPETITIVE LANDSCAPE 121
11.1 OVERVIEW 121
11.2 COMPANY PRODUCT FOOTPRINT 122
FIGURE 18 PRODUCT PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET 122
11.3 COMPETITIVE SCENARIO 123
TABLE 133 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2020–JANUARY 2021 123
12 COMPANY PROFILES 125
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ENTEROME 125
12.2 SERES THERAPEUTICS 128
FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2019) 128
12.3 4D PHARMA PLC 130
FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2019) 130
12.4 EVELO BIOSCIENCES, INC. 133
FIGURE 21 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2019) 133
12.5 OPTIBIOTIX HEALTH PLC 135
FIGURE 22 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2019) 135
12.6 SYNLOGIC 145
FIGURE 23 SYNLOGIC: COMPANY SNAPSHOT (2019) 145
12.7 SECOND GENOME 147
12.8 VEDANTA BIOSCIENCES, INC. 149
12.9 FERRING PHARMACEUTICALS 151
12.10 VITHERA PHARMACEUTICALS, INC. 153
12.11 BIOMX 154
FIGURE 24 BIOMX: COMPANY SNAPSHOT (2019) 154
12.12 DUPOINT 156
FIGURE 25 DU PONT: COMPANY SNAPSHOT (2019) 157
12.13 KALEIDO 159
FIGURE 26 KALEIDO: COMPANY SNAPSHOT (2019) 159
12.14 YSOPIA BIOSCIENCE 161
12.15 FLIGHTPATH 163
12.16 FINCH THERAPEUTICS GROUP, INC 164
12.17 QUANTBIOME, INC. (DBA THRYVE) 165
12.18 VIOME, INC. 165
12.19 DAYTWO INC 166
12.20 BIOHM 166
12.21 ATLAS BIOMED GROUP LIMITED. 167
12.22 BIONE 167
12.23 LUXIA SCIENTIFIC 168
12.24 SUN GENOMICS 168
12.25 METABIOMICS 169
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 170
13.1 DISCUSSION GUIDE 170
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 173
13.3 AVAILABLE CUSTOMIZATIONS 175
13.4 RELATED REPORTS 175
13.5 AUTHOR DETAILS 176



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のヒトマイクロバイオーム市場予測(~2028年):製品別(プレバイオティクス、プロバイオティクス、食品、診断検査、薬剤)、用途別(治療、診断)、疾患別(感染性、代謝/内分泌)、研究技術別(ゲノミクス、プロテオミクス、メタボロミクス)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆